PCIDB

KNApSAcK Metabolite C00002145

Metabolite

KNApSAcK Entry

id C00002145
Name Camptothecin
CAS RN 7689-03-4
Standard InChI InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
Standard InChI (Main Layer) InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3

Cluster

Phytochemical cluster No. 7
KCF-S cluster No. 3696

Link

ChEMBL

By standard InChI CHEMBL65
By standard InChI Main Layer CHEMBL65 CHEMBL276820 CHEMBL71836

KEGG

By LinkDB C01897

CTD

By CAS RN D002166

Human Protein / Gene in interaction

140 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL65 CHEMBL1741321 (2) CHEMBL1909136 (2)
1 / 0
P42345 Serine/threonine-protein kinase mTOR Enzyme CHEMBL65 CHEMBL1613805 (1) CHEMBL1614293 (1)
0 / 0
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL65 CHEMBL71836 CHEMBL1613992 (3) CHEMBL1613995 (1)
7 / 44
Q07820 Induced myeloid leukemia cell differentiation protein Mcl-1 Other cytosolic protein CHEMBL65 CHEMBL2014669 (1) CHEMBL2014671 (1)
0 / 0
Q16637 Survival motor neuron protein Unclassified protein CHEMBL65 CHEMBL1613842 (3)
4 / 2
Q99700 Ataxin-2 Unclassified protein CHEMBL65 CHEMBL2114784 (2)
1 / 1
P49798 Regulator of G-protein signaling 4 Unclassified protein CHEMBL65 CHEMBL1794499 (1)
2 / 0
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL65 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL65 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL65 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL65 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL65 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL65 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL65 CHEMBL1909176 (2)
0 / 0
P04062 Glucosylceramidase Enzyme CHEMBL65 CHEMBL71836 CHEMBL1613818 (5)
6 / 4
P10253 Lysosomal alpha-glucosidase Hydrolase CHEMBL65 CHEMBL1614175 (1)
1 / 1
P29466 Caspase-1 C14 CHEMBL65 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL65 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL65 CHEMBL1909199 (2)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL65 CHEMBL1909197 (2)
2 / 2
O14757 Serine/threonine-protein kinase Chk1 Chk1 CHEMBL65 CHEMBL891240 (1) CHEMBL894151 (1)
CHEMBL894152 (1) CHEMBL894153 (1)
CHEMBL894154 (1)
0 / 0
P02545 Prelamin-A/C Unclassified protein CHEMBL65 CHEMBL1614310 (1) CHEMBL1614544 (2)
11 / 10
Q9NZJ5 Eukaryotic translation initiation factor 2-alpha kinase 3 Pek CHEMBL65 CHEMBL1614254 (1) CHEMBL1614023 (1)
1 / 2
P16473 Thyrotropin receptor Glycohormone receptor CHEMBL65 CHEMBL1614281 (1) CHEMBL1614361 (1)
3 / 2
P00918 Carbonic anhydrase 2 Lyase CHEMBL65 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL65 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL65 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL65 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL65 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL65 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL65 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL65 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL65 CHEMBL1909093 (2)
0 / 0
P02768 Serum albumin Secreted protein CHEMBL65 CHEMBL702880 (1) CHEMBL702881 (1)
CHEMBL702882 (1) CHEMBL702883 (1)
CHEMBL702885 (1)
0 / 0
P08183 Multidrug resistance protein 1 drug CHEMBL65 CHEMBL2078581 (1)
1 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL65 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL65 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL65 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL65 CHEMBL1741325 (2) CHEMBL1909135 (2)
0 / 1
P54132 Bloom syndrome protein Enzyme CHEMBL65 CHEMBL1614522 (1) CHEMBL1614067 (1)
1 / 2
Q9HBX9 Relaxin receptor 1 Relaxin receptor CHEMBL65 CHEMBL1613930 (1)
0 / 0
Q9NR56 Muscleblind-like protein 1 Unclassified protein CHEMBL65 CHEMBL1614166 (2)
1 / 0
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL65 CHEMBL1909203 (2)
1 / 11
P11387 DNA topoisomerase 1 Isomerase CHEMBL65 CHEMBL276820 CHEMBL71836 CHEMBL664390 (1) CHEMBL664396 (1)
CHEMBL664398 (1) CHEMBL664401 (1)
CHEMBL664403 (1) CHEMBL664404 (1)
CHEMBL664406 (1) CHEMBL665071 (1)
CHEMBL665073 (1) CHEMBL664008 (1)
CHEMBL664469 (1) CHEMBL663638 (1)
CHEMBL663645 (1) CHEMBL663649 (1)
CHEMBL665550 (1) CHEMBL665552 (1)
CHEMBL663903 (1) CHEMBL669796 (1)
CHEMBL669800 (1) CHEMBL669802 (1)
CHEMBL669814 (1) CHEMBL857050 (1)
CHEMBL813218 (1) CHEMBL813219 (1)
CHEMBL813220 (1) CHEMBL813221 (1)
CHEMBL873882 (3) CHEMBL813222 (1)
CHEMBL813223 (1) CHEMBL815516 (1)
CHEMBL821422 (1) CHEMBL821424 (1)
CHEMBL821433 (1) CHEMBL877105 (1)
CHEMBL840259 (1) CHEMBL827216 (1)
CHEMBL829210 (1) CHEMBL832446 (1)
CHEMBL832447 (1) CHEMBL832451 (1)
CHEMBL835604 (1) CHEMBL832068 (1)
CHEMBL861983 (1) CHEMBL917825 (1)
CHEMBL919343 (1) CHEMBL920240 (1)
CHEMBL920241 (1) CHEMBL920242 (1)
CHEMBL904089 (1) CHEMBL891737 (1)
CHEMBL923907 (1) CHEMBL935691 (1)
CHEMBL956191 (1) CHEMBL978890 (1)
CHEMBL996007 (1) CHEMBL996008 (1)
CHEMBL996009 (1) CHEMBL997909 (1)
CHEMBL969978 (1) CHEMBL973807 (1)
CHEMBL1003401 (1) CHEMBL962290 (1)
CHEMBL1018862 (1) CHEMBL1062111 (1)
CHEMBL1062548 (1) CHEMBL1062549 (1)
CHEMBL1062556 (1) CHEMBL1052620 (1)
CHEMBL1061873 (1) CHEMBL1052728 (1)
CHEMBL1045716 (1) CHEMBL1065973 (1)
CHEMBL1072847 (1) CHEMBL1072848 (1)
CHEMBL1066568 (1) CHEMBL1068938 (1)
CHEMBL1068939 (1) CHEMBL1067579 (1)
CHEMBL1067580 (1) CHEMBL1101514 (1)
CHEMBL1101515 (1) CHEMBL1108448 (1)
CHEMBL1117453 (1) CHEMBL1117454 (1)
CHEMBL1166365 (1) CHEMBL1175433 (1)
CHEMBL1217333 (1) CHEMBL1246695 (1)
CHEMBL1246696 (1) CHEMBL1287271 (1)
CHEMBL1287272 (1) CHEMBL1647797 (1)
CHEMBL1645637 (1) CHEMBL1648862 (1)
CHEMBL1768647 (1) CHEMBL1785100 (1)
CHEMBL1785647 (1) CHEMBL1785648 (1)
CHEMBL1810469 (1) CHEMBL1810470 (1)
CHEMBL1816482 (1) CHEMBL1828129 (1)
CHEMBL1837615 (1) CHEMBL1949180 (1)
CHEMBL1949181 (1) CHEMBL1949383 (1)
CHEMBL2026476 (1) CHEMBL2027009 (1)
CHEMBL2045777 (1) CHEMBL2162605 (1)
CHEMBL2162607 (1) CHEMBL2162608 (1)
CHEMBL2162609 (1) CHEMBL2166589 (1)
CHEMBL2175077 (1) CHEMBL2176318 (1)
CHEMBL2176319 (1) CHEMBL2317051 (1)
CHEMBL2339797 (1)
0 / 0
P11388 DNA topoisomerase 2-alpha Isomerase CHEMBL65 CHEMBL861984 (1) CHEMBL944912 (1)
CHEMBL944913 (1) CHEMBL996010 (1)
CHEMBL996011 (1) CHEMBL1045717 (1)
CHEMBL1072876 (1) CHEMBL1101516 (1)
CHEMBL1101517 (1) CHEMBL1108449 (1)
CHEMBL1647796 (1)
0 / 0
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL65 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL65 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL65 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL65 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL65 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL65 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL65 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL65 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL65 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL65 CHEMBL1909166 (2)
1 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL65 CHEMBL71836 CHEMBL1614458 (5)
0 / 0
P68871 Hemoglobin subunit beta Secreted protein CHEMBL65 CHEMBL1614204 (1) CHEMBL1614404 (1)
4 / 4
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL65 CHEMBL1909133 (2)
0 / 0
Q16665 Hypoxia-inducible factor 1-alpha Transcription Factor CHEMBL65 CHEMBL1614456 (2) CHEMBL1613803 (2)
0 / 0
Q92830 Histone acetyltransferase KAT2A Enzyme CHEMBL65 CHEMBL1738606 (1)
0 / 0
P42858 Huntingtin Unclassified protein CHEMBL65 CHEMBL1613918 (1)
1 / 1
O75496 Geminin Unclassified protein CHEMBL65 CHEMBL1613941 (1) CHEMBL1738636 (1)
0 / 0
P51151 Ras-related protein Rab-9A Unclassified protein CHEMBL65 CHEMBL1613838 (2)
0 / 0
P09651 Heterogeneous nuclear ribonucleoprotein A1 Unclassified protein CHEMBL65 CHEMBL1960739 (2) CHEMBL1960740 (1)
CHEMBL1960741 (1) CHEMBL1960747 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL65 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL65 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL65 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL65 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL65 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL65 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL65 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL65 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL65 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL65 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL65 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL65 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL65 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL65 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL65 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL65 CHEMBL1909119 (2)
0 / 0
P42226 Signal transducer and activator of transcription 6 Unclassified protein CHEMBL71836 CHEMBL1614338 (1) CHEMBL1614070 (1)
0 / 0
P83916 Chromobox protein homolog 1 Unclassified protein CHEMBL65 CHEMBL1738610 (1)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL65 CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL65 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL65 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL65 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL65 CHEMBL1909109 (2)
2 / 0
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL65 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL65 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL65 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL65 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL65 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL65 CHEMBL1909108 (2)
0 / 0
P06280 Alpha-galactosidase A Enzyme CHEMBL65 CHEMBL71836 CHEMBL1614011 (1) CHEMBL1614217 (6)
CHEMBL1614369 (6)
1 / 1
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL65 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL65 CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL65 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL65 CHEMBL1741322 (2) CHEMBL1909132 (2)
0 / 0
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 Enzyme CHEMBL65 CHEMBL1613910 (2) CHEMBL1614227 (2)
3 / 3
P15428 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Enzyme CHEMBL65 CHEMBL71836 CHEMBL1614038 (5)
2 / 2
Q01453 Peripheral myelin protein 22 Unclassified protein CHEMBL65 CHEMBL1614171 (1)
5 / 2
Q96QE3 ATPase family AAA domain-containing protein 5 Unclassified protein CHEMBL65 CHEMBL1738588 (1) CHEMBL1738675 (1)
CHEMBL1737868 (1)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL65 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL65 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL65 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL65 CHEMBL641507 (1) CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL65 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL65 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL65 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL65 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL65 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL65 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL65 CHEMBL1909168 (2)
0 / 0
P19838 Nuclear factor NF-kappa-B p105 subunit Transcription Factor CHEMBL65 CHEMBL1614274 (1) CHEMBL1613823 (1)
0 / 0
Q02880 DNA topoisomerase 2-beta Isomerase CHEMBL65 CHEMBL813453 (1) CHEMBL861984 (1)
0 / 0
P16050 Arachidonate 15-lipoxygenase Enzyme CHEMBL65 CHEMBL1614240 (1)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL65 CHEMBL1613777 (1) CHEMBL1741323 (2)
CHEMBL1909134 (2)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL65 CHEMBL1614108 (1) CHEMBL1613886 (1)
CHEMBL1741324 (2) CHEMBL1909138 (2)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL65 CHEMBL1909137 (2)
0 / 0
Q9UNA4 DNA polymerase iota Enzyme CHEMBL65 CHEMBL1794483 (1)
0 / 0
Q99549 M-phase phosphoprotein 8 Unclassified protein CHEMBL65 CHEMBL1738402 (1)
0 / 0
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL65 CHEMBL1737980 (1) CHEMBL1738184 (1)
0 / 0
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL65 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL65 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL65 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL65 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL65 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL65 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL65 CHEMBL1909128 (2)
0 / 0
O14746 Telomerase reverse transcriptase Enzyme CHEMBL65 CHEMBL990278 (1)
5 / 5
B2RXH2 Lysine-specific demethylase 4E Enzyme CHEMBL65 CHEMBL71836 CHEMBL1613914 (6)
0 / 0
P40225 Thrombopoietin Unclassified protein CHEMBL65 CHEMBL1614086 (1) CHEMBL1614034 (1)
1 / 1
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL65 CHEMBL1738442 (2)
0 / 0
O00255 Menin Unclassified protein CHEMBL71836 CHEMBL1614531 (1)
2 / 5
Q03164 Histone-lysine N-methyltransferase 2A Enzyme CHEMBL71836 CHEMBL1614531 (1)
1 / 3
P30874 Somatostatin receptor type 2 Somatostatin receptor CHEMBL65 CHEMBL700687 (1)
0 / 0
P31391 Somatostatin receptor type 4 Somatostatin receptor CHEMBL65 CHEMBL700687 (1)
0 / 0
P32745 Somatostatin receptor type 3 Somatostatin receptor CHEMBL65 CHEMBL700687 (1)
0 / 0
P35346 Somatostatin receptor type 5 Somatostatin receptor CHEMBL65 CHEMBL700687 (1)
0 / 0
P30872 Somatostatin receptor type 1 Somatostatin receptor CHEMBL65 CHEMBL700687 (1)
0 / 0

CTD interaction (168)

compound gene gene name gene description interaction interaction type form reference
pmid
D002166 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Camptothecin results in decreased expression of ABCB1 protein decreases expression
protein 10692111
D002166 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein results in decreased susceptibility to Camptothecin analog decreases response to substance
protein 11778547
D002166 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Camptothecin inhibits the reaction [ABCC1 results in decreased susceptibility to Daunorubicin] decreases reaction
/ decreases response to substance
12115804
D002166 375790 AGRN
agrin Camptothecin results in increased expression of AGRN mRNA increases expression
mRNA 17374387
D002166 213 ALB
PRO0883
PRO0903
PRO1341
albumin Camptothecin analog binds to ALB protein affects binding
protein 17378599
D002166 213 ALB
PRO0883
PRO0903
PRO1341
albumin Camptothecin binds to ALB protein affects binding
protein 10803926
D002166 213 ALB
PRO0883
PRO0903
PRO1341
albumin CTSB protein results in increased cleavage of [Camptothecin analog binds to ALB protein] affects binding
/ increases cleavage
protein 17378599
D002166 307 ANXA4
ANX4
PIG28
ZAP36
annexin A4 Camptothecin results in increased expression of ANXA4 mRNA increases expression
mRNA 17374387
D002166 581 BAX
BCL2L4
BCL2-associated X protein Camptothecin affects the cleavage of and results in decreased expression of BAX protein affects cleavage
/ decreases expression
protein 19481069
D002166 581 BAX
BCL2L4
BCL2-associated X protein [Camptothecin co-treated with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] results in decreased expression of BAX protein affects cotreatment
/ decreases expression
protein 19481069
D002166 581 BAX
BCL2L4
BCL2-associated X protein Camptothecin results in increased activity of BAX protein increases activity
protein 15665116
D002166 581 BAX
BCL2L4
BCL2-associated X protein Camptothecin results in increased expression of BAX protein increases expression
protein 17555331
D002166 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in decreased expression of BCL2 protein] decreases expression
/ increases reaction
protein 19481069
D002166 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 BCL2 results in decreased susceptibility to Camptothecin decreases response to substance
10896673
D002166 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Camptothecin results in decreased expression of BCL2 protein decreases expression
protein 9664115
10692111
19481069
D002166 637 BID
FP497
BH3 interacting domain death agonist [Camptothecin co-treated with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] results in increased cleavage of and results in decreased expression of BID protein affects cotreatment
/ decreases expression
/ increases cleavage
protein 19481069
D002166 637 BID
FP497
BH3 interacting domain death agonist [Camptothecin co-treated with FAS protein] results in increased cleavage of BID protein affects cotreatment
/ increases cleavage
protein 19633536
D002166 637 BID
FP497
BH3 interacting domain death agonist Camptothecin results in increased cleavage of and results in decreased expression of BID protein decreases expression
/ increases cleavage
protein 19481069
D002166 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [Butyrates co-treated with Camptothecin] results in decreased expression of BIRC5 protein affects cotreatment
/ decreases expression
protein 16061681
D002166 672 BRCA1
BRCAI
BRCC1
BROVCA1
IRIS
PNCA4
PPP1R53
PSCP
RNF53
breast cancer 1, early onset Camptothecin results in decreased expression of BRCA1 mRNA decreases expression
mRNA 10344722
D002166 675 BRCA2
BRCC2
BROVCA2
FACD
FAD
FAD1
FANCB
FANCD
FANCD1
GLM3
PNCA2
breast cancer 2, early onset Camptothecin results in decreased expression of BRCA2 mRNA decreases expression
mRNA 10344722
D002166 51719 CAB39
MO25
calcium binding protein 39 Camptothecin results in decreased expression of CAB39 mRNA decreases expression
mRNA 17374387
D002166 835 CASP2
CASP-2
ICH1
NEDD-2
NEDD2
PPP1R57
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) Camptothecin results in increased expression of CASP2 mRNA alternative form increases expression
mRNA 14757846
D002166 835 CASP2
CASP-2
ICH1
NEDD-2
NEDD2
PPP1R57
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) Camptothecin results in increased splicing of CASP2 mRNA increases splicing
mRNA 14757846
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) 15-deoxyprostaglandin J2 promotes the reaction [Camptothecin results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 21683069
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 19481069
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Camptothecin co-treated with FAS protein] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 15958570
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP3 protein affects cotreatment
/ increases cleavage
protein 19633536
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Camptothecin promotes the reaction [15-deoxyprostaglandin J2 results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 21683069
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Camptothecin results in increased activity of CASP3 protein increases activity
protein 15862279
16273314
16962673
19481069
21683069
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Camptothecin results in increased cleavage of CASP3 protein increases cleavage
protein 10896673
16756956
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) SMN1 mRNA affects the reaction [Camptothecin results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 15862279
D002166 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) THBS1 protein inhibits the reaction [Camptothecin results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 16962673
D002166 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Camptothecin results in increased activity of CASP8 protein] decreases reaction
/ increases activity
protein 15475000
D002166 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Camptothecin affects the cleavage of CASP8 protein affects cleavage
protein 10896673
D002166 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Camptothecin co-treated with FAS protein] results in increased activity of CASP8 protein affects cotreatment
/ increases activity
protein 15958570
D002166 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP8 protein affects cotreatment
/ increases cleavage
protein 19633536
D002166 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Camptothecin results in increased activity of CASP8 protein increases activity
protein 15475000
D002166 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Lithium inhibits the reaction [Camptothecin results in increased activity of CASP8 protein] decreases reaction
/ increases activity
protein 15475000
D002166 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Camptothecin co-treated with FAS protein] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
protein 15958570
D002166 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP9 protein affects cotreatment
/ increases cleavage
protein 19633536
D002166 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Camptothecin results in increased cleavage of CASP9 protein increases cleavage
protein 10896673
D002166 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Camptothecin results in decreased expression of CCL2 protein decreases expression
protein 20116850
D002166 6351 CCL4
ACT2
AT744.1
G-26
HC21
LAG-1
LAG1
MIP-1-beta
MIP1B
MIP1B1
SCYA2
SCYA4
chemokine (C-C motif) ligand 4 Camptothecin results in decreased expression of CCL4 protein decreases expression
protein 20116850
D002166 6352 CCL5
D17S136E
RANTES
SCYA5
SIS-delta
SISd
TCP228
eoCP
chemokine (C-C motif) ligand 5 Camptothecin results in decreased expression of CCL5 protein decreases expression
protein 20116850
D002166 891 CCNB1
CCNB
cyclin B1 [Butyrates co-treated with Camptothecin] results in decreased expression of CCNB1 protein affects cotreatment
/ decreases expression
protein 16061681
D002166 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Camptothecin results in increased phosphorylation of and results in decreased activity of CDK2 protein decreases activity
/ increases phosphorylation
protein 15141020
D002166 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Aspirin inhibits the reaction [Camptothecin results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 19212664
D002166 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Camptothecin results in increased expression of CDKN1A protein increases expression
protein 9673414
17555331
19212664
D002166 634 CEACAM1
BGP
BGP1
BGPI
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) Camptothecin results in increased expression of CEACAM1 mRNA increases expression
mRNA 17374387
D002166 10153 CEBPZ
CBF
CBF2
HSP-CBF
NOC1
CCAAT/enhancer binding protein (C/EBP), zeta Camptothecin results in decreased expression of CEBPZ mRNA decreases expression
mRNA 17374387
D002166 1508 CTSB
APPS
CPSB
cathepsin B (EC:3.4.22.1) CTSB protein results in increased cleavage of [Camptothecin analog binds to ALB protein] affects binding
/ increases cleavage
protein 17378599
D002166 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin affects the localization of CYCS protein] affects localization
/ increases reaction
protein 19481069
D002166 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic Camptothecin affects the localization of CYCS protein affects localization
protein 19481069
D002166 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) Camptothecin inhibits the reaction [Fluorouracil results in increased expression of DPYD mRNA] decreases reaction
/ increases expression
mRNA 16568373
D002166 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) Camptothecin results in decreased activity of DPYD protein decreases activity
protein 16568373
D002166 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) Camptothecin results in decreased expression of DPYD mRNA decreases expression
mRNA 16568373
D002166 9538 EI24
EPG4
PIG8
TP53I8
etoposide induced 2.4 Camptothecin results in increased expression of EI24 mRNA increases expression
mRNA 17374387
D002166 2033 EP300
KAT3B
RSTS2
p300
E1A binding protein p300 (EC:2.3.1.48) Camptothecin results in decreased expression of EP300 mRNA decreases expression
mRNA 10344722
D002166 2033 EP300
KAT3B
RSTS2
p300
E1A binding protein p300 (EC:2.3.1.48) Camptothecin results in decreased expression of EP300 protein decreases expression
protein 10344722
D002166 9852 EPM2AIP1
EPM2A (laforin) interacting protein 1 Camptothecin results in increased expression of EPM2AIP1 mRNA increases expression
mRNA 17374387
D002166 2067 ERCC1
COFS4
RAD10
UV20
excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) ERCC1 protein promotes the reaction [2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide promotes the reaction [Camptothecin results in increased expression of H2AFX protein]] increases expression
/ increases reaction
protein 21227924
D002166 2072 ERCC4
ERCC11
FANCQ
RAD1
XPF
excision repair cross-complementing rodent repair deficiency, complementation group 4 ERCC4 protein promotes the reaction [2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide promotes the reaction [Camptothecin results in increased expression of H2AFX protein]] increases expression
/ increases reaction
protein 21227924
D002166 2072 ERCC4
ERCC11
FANCQ
RAD1
XPF
excision repair cross-complementing rodent repair deficiency, complementation group 4 ERCC4 protein results in decreased susceptibility to Camptothecin decreases response to substance
protein 21227924
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Camptothecin results in increased expression of and affects the localization of FAS protein] affects localization
/ decreases reaction
/ increases expression
protein 15475000
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [Camptothecin co-treated with FAS protein] results in decreased expression of XIAP protein affects cotreatment
/ decreases expression
protein 19633536
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [Camptothecin co-treated with FAS protein] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 15958570
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [Camptothecin co-treated with FAS protein] results in increased activity of CASP8 protein affects cotreatment
/ increases activity
protein 15958570
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [Camptothecin co-treated with FAS protein] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
protein 15958570
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [Camptothecin co-treated with FAS protein] results in increased cleavage of BID protein affects cotreatment
/ increases cleavage
protein 19633536
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP3 protein affects cotreatment
/ increases cleavage
protein 19633536
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP8 protein affects cotreatment
/ increases cleavage
protein 19633536
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP9 protein affects cotreatment
/ increases cleavage
protein 19633536
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Camptothecin results in increased expression of and affects the localization of FAS protein affects localization
/ increases expression
protein 15475000
D002166 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Lithium inhibits the reaction [Camptothecin results in increased expression of and affects the localization of FAS protein] affects localization
/ decreases reaction
/ increases expression
protein 15475000
D002166 2232 FDXR
ADXR
ferredoxin reductase (EC:1.18.1.6) Camptothecin results in increased expression of FDXR mRNA increases expression
mRNA 17374387
D002166 2395 FXN
CyaY
FA
FARR
FRDA
X25
frataxin (EC:1.16.3.1) Camptothecin results in increased expression of FXN protein increases expression
protein 23418481
D002166 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) Camptothecin results in increased expression of GSTP1 protein increases expression
protein 15500952
D002166 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) GSTP1 protein polymorphism results in decreased susceptibility to Camptothecin decreases response to substance
protein 15500952
D002166 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) GSTP1 protein results in decreased susceptibility to Camptothecin decreases response to substance
protein 14732228
15500952
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide promotes the reaction [Camptothecin results in increased expression of H2AFX protein] increases expression
/ increases reaction
protein 21227924
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide promotes the reaction [Camptothecin results in increased expression of H2AFX protein]] decreases reaction
/ increases expression
/ increases reaction
protein 21227924
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X Camptothecin results in increased expression of H2AFX protein increases expression
protein 21227924
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X ERCC1 protein promotes the reaction [2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide promotes the reaction [Camptothecin results in increased expression of H2AFX protein]] increases expression
/ increases reaction
protein 21227924
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X ERCC4 protein promotes the reaction [2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide promotes the reaction [Camptothecin results in increased expression of H2AFX protein]] increases expression
/ increases reaction
protein 21227924
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X H2AFX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin] decreases reaction
/ increases response to substance
gene 21693595
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X [MIR138-1 results in decreased expression of H2AFX] which results in increased susceptibility to Camptothecin decreases expression
/ increases response to substance
21693595
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X TDP1 protein inhibits the reaction [2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide promotes the reaction [Camptothecin results in increased expression of H2AFX protein]] decreases reaction
/ increases expression
/ increases reaction
protein 21227924
D002166 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AFX protein] decreases reaction
/ increases expression
protein 21227924
D002166 3183 HNRNPC
C1
C2
HNRNP
HNRPC
SNRPC
heterogeneous nuclear ribonucleoprotein C (C1/C2) [HNRNPC protein binds to HNRNPC protein alternative form] which results in decreased susceptibility to Camptothecin affects binding
/ decreases response to substance
protein 16960656
D002166 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta IL1B protein results in decreased susceptibility to Camptothecin decreases response to substance
protein 16356833
D002166 3570 IL6R
CD126
IL-6R-1
IL-6RA
IL6Q
IL6RA
IL6RQ
gp80
interleukin 6 receptor Camptothecin results in decreased expression of IL6R protein modified form decreases expression
protein 20116850
D002166 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Camptothecin results in decreased expression of IL8 protein decreases expression
protein 20116850
D002166 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Camptothecin results in increased secretion of IL8 protein increases secretion
protein 18191106
D002166 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ciprofloxacin inhibits the reaction [Camptothecin results in increased secretion of IL8 protein] decreases reaction
/ increases secretion
protein 18191106
D002166 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 IL8 protein results in decreased susceptibility to Camptothecin decreases response to substance
protein 16356833
D002166 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 moxifloxacin inhibits the reaction [Camptothecin results in increased secretion of IL8 protein] decreases reaction
/ increases secretion
protein 18191106
D002166 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Camptothecin results in increased expression of JUN protein increases expression
protein 15585644
D002166 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Camptothecin results in increased phosphorylation of JUN protein increases phosphorylation
protein 15585644
D002166 3956 LGALS1
GAL1
GBP
lectin, galactoside-binding, soluble, 1 Camptothecin results in decreased expression of LGALS1 mRNA decreases expression
mRNA 19483324
D002166 3956 LGALS1
GAL1
GBP
lectin, galactoside-binding, soluble, 1 Camptothecin results in decreased expression of LGALS1 protein decreases expression
protein 19483324
D002166 5606 MAP2K3
MAPKK3
MEK3
MKK3
PRKMK3
SAPKK-2
SAPKK2
mitogen-activated protein kinase kinase 3 (EC:2.7.12.2) Camptothecin results in increased expression of MAP2K3 mRNA increases expression
mRNA 17374387
D002166 4217 MAP3K5
ASK1
MAPKKK5
MEKK5
mitogen-activated protein kinase kinase kinase 5 (EC:2.7.11.25) Camptothecin results in decreased expression of MAP3K5 mRNA decreases expression
mRNA 17374387
D002166 5601 MAPK9
JNK-55
JNK2
JNK2A
JNK2ALPHA
JNK2B
JNK2BETA
PRKM9
SAPK
SAPK1a
p54a
p54aSAPK
mitogen-activated protein kinase 9 (EC:2.7.11.24) Camptothecin results in increased phosphorylation of MAPK9 protein increases phosphorylation
protein 15585644
D002166 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau Camptothecin results in decreased expression of MAPT mRNA decreases expression
mRNA 16930453
D002166 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau Camptothecin results in decreased expression of MAPT protein decreases expression
protein 16930453
D002166 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase Camptothecin results in increased expression of MDM2 protein increases expression
protein 17555331
D002166 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) Camptothecin results in decreased expression of MGMT mRNA decreases expression
mRNA 18492797
D002166 406929 MIR138-1
MIRN138-1
microRNA 138-1 H2AFX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin] decreases reaction
/ increases response to substance
21693595
D002166 406929 MIR138-1
MIRN138-1
microRNA 138-1 [MIR138-1 results in decreased expression of H2AFX] which results in increased susceptibility to Camptothecin decreases expression
/ increases response to substance
21693595
D002166 406929 MIR138-1
MIRN138-1
microRNA 138-1 MIR138-1 results in increased susceptibility to Camptothecin increases response to substance
21693595
D002166 8440 NCK2
GRB4
NCKbeta
NCK adaptor protein 2 Camptothecin results in decreased expression of NCK2 mRNA decreases expression
mRNA 17374387
D002166 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Camptothecin results in increased cleavage of PARP1 protein increases cleavage
protein 11741290
15585644
16962673
19559722
D002166 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) RBL2 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
protein 15585644
D002166 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) THBS1 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
protein 16962673
D002166 1263 PLK3
CNK
FNK
PRK
polo-like kinase 3 (EC:2.7.11.21) Camptothecin results in increased expression of PLK3 mRNA increases expression
mRNA 17374387
D002166 84152 PPP1R1B
DARPP-32
DARPP32
protein phosphatase 1, regulatory (inhibitor) subunit 1B (EC:3.1.3.16) PPP1R1B protein alternative form results in decreased susceptibility to Camptothecin decreases response to substance
protein 16061638
D002166 84152 PPP1R1B
DARPP-32
DARPP32
protein phosphatase 1, regulatory (inhibitor) subunit 1B (EC:3.1.3.16) PPP1R1B protein results in decreased susceptibility to Camptothecin decreases response to substance
protein 16061638
D002166 9055 PRC1
ASE1
protein regulator of cytokinesis 1 Camptothecin results in decreased expression of PRC1 mRNA decreases expression
mRNA 17374387
D002166 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase Camptothecin results in decreased expression of RAD51 mRNA decreases expression
mRNA 10344722
D002166 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase Camptothecin results in decreased expression of RAD51 protein decreases expression
protein 10344722
D002166 5889 RAD51C
BROVCA3
FANCO
R51H3
RAD51L2
RAD51 paralog C RAD51C gene mutant form results in increased susceptibility to Camptothecin increases response to substance
gene 20400963
D002166 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Camptothecin results in increased phosphorylation of RB1 protein increases phosphorylation
protein 15585644
D002166 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 RB1 protein affects the susceptibility to Camptothecin affects response to substance
protein 14704340
D002166 5933 RBL1
CP107
PRB1
p107
retinoblastoma-like 1 (p107) Camptothecin results in decreased expression of RBL1 protein decreases expression
protein 15585644
D002166 5934 RBL2
P130
Rb2
retinoblastoma-like 2 (p130) RBL2 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
protein 15585644
D002166 5934 RBL2
P130
Rb2
retinoblastoma-like 2 (p130) RBL2 protein results in decreased susceptibility to Camptothecin decreases response to substance
protein 15585644
D002166 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A RELA results in increased susceptibility to Camptothecin increases response to substance
21737676
D002166 6382 SDC1
CD138
SDC
SYND1
syndecan
syndecan 1 Camptothecin results in increased expression of SDC1 mRNA increases expression
mRNA 17374387
D002166 6606 SMN1
BCD541
GEMIN1
SMA
SMA1
SMA2
SMA3
SMA4
SMA@
SMN
SMNT
T-BCD541
TDRD16A
survival of motor neuron 1, telomeric SMN1 mRNA affects the reaction [Camptothecin results in increased activity of CASP3 protein] affects reaction
/ increases activity
mRNA 15862279
D002166 6606 SMN1
BCD541
GEMIN1
SMA
SMA1
SMA2
SMA3
SMA4
SMA@
SMN
SMNT
T-BCD541
TDRD16A
survival of motor neuron 1, telomeric SMN1 protein results in increased susceptibility to Camptothecin increases response to substance
protein 15862279
D002166 55512 SMPD3
NSMASE2
sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) (EC:3.1.4.12) Camptothecin results in increased expression of SMPD3 mRNA increases expression
mRNA 19698806
D002166 6667 SP1
Sp1 transcription factor Camptothecin results in increased activity of SP1 protein increases activity
protein 11261509
D002166 6667 SP1
Sp1 transcription factor mithramycin A inhibits the reaction [Camptothecin results in increased activity of SP1 protein] decreases reaction
/ increases activity
protein 11261509
D002166 6670 SP3
SPR2
Sp3 transcription factor Camptothecin results in increased activity of SP3 protein increases activity
protein 11261509
D002166 6670 SP3
SPR2
Sp3 transcription factor mithramycin A inhibits the reaction [Camptothecin results in increased activity of SP3 protein] decreases reaction
/ increases activity
protein 11261509
D002166 6890 TAP1
ABC17
ABCB2
APT1
D6S114E
PSF-1
PSF1
RING4
TAP1*0102N
TAP1N
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) Camptothecin results in increased expression of TAP1 mRNA increases expression
mRNA 17374387
D002166 30851 TAX1BP3
TIP-1
Tax1 (human T-cell leukemia virus type I) binding protein 3 Camptothecin results in increased expression of TAX1BP3 mRNA increases expression
mRNA 17374387
D002166 55775 TDP1
tyrosyl-DNA phosphodiesterase 1 (EC:3.1.4.-) TDP1 protein inhibits the reaction [2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide promotes the reaction [Camptothecin results in increased expression of H2AFX protein]] decreases reaction
/ increases expression
/ increases reaction
protein 21227924
D002166 55775 TDP1
tyrosyl-DNA phosphodiesterase 1 (EC:3.1.4.-) TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AFX protein] decreases reaction
/ increases expression
protein 21227924
D002166 7057 THBS1
THBS
THBS-1
TSP
TSP-1
TSP1
thrombospondin 1 Camptothecin results in decreased expression of THBS1 mRNA decreases expression
mRNA 16962673
D002166 7057 THBS1
THBS
THBS-1
TSP
TSP-1
TSP1
thrombospondin 1 Camptothecin results in decreased secretion of THBS1 protein decreases secretion
protein 16962673
D002166 7057 THBS1
THBS
THBS-1
TSP
TSP-1
TSP1
thrombospondin 1 THBS1 protein inhibits the reaction [Camptothecin results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 16962673
D002166 7057 THBS1
THBS
THBS-1
TSP
TSP-1
TSP1
thrombospondin 1 THBS1 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
protein 16962673
D002166 8744 TNFSF9
4-1BB-L
CD137L
tumor necrosis factor (ligand) superfamily, member 9 Camptothecin results in increased expression of TNFSF9 mRNA increases expression
mRNA 17374387
D002166 7150 TOP1
TOPI
topoisomerase (DNA) I (EC:5.99.1.2) Camptothecin analog results in decreased activity of TOP1 protein decreases activity
protein 21056033
D002166 7150 TOP1
TOPI
topoisomerase (DNA) I (EC:5.99.1.2) Camptothecin results in decreased activity of TOP1 protein decreases activity
protein 12097280
21227924
D002166 7150 TOP1
TOPI
topoisomerase (DNA) I (EC:5.99.1.2) [Ciprofloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein affects cotreatment
/ decreases activity
protein 18191106
D002166 7150 TOP1
TOPI
topoisomerase (DNA) I (EC:5.99.1.2) [moxifloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein affects cotreatment
/ decreases activity
protein 18191106
D002166 7150 TOP1
TOPI
topoisomerase (DNA) I (EC:5.99.1.2) TOP1 protein mutant form results in decreased susceptibility to Camptothecin decreases response to substance
protein 12097280
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased expression of TP53 protein] increases expression
/ increases reaction
protein 19481069
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] decreases reaction
/ increases expression
protein 17555331
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Camptothecin results in increased expression of TP53 protein increases expression
protein 9673414
12082016
17555331
19481069
20978201
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Camptothecin results in increased glutathionylation of TP53 protein increases glutathionylation
protein 17555331
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Camptothecin results in increased phosphorylation of TP53 protein increases phosphorylation
protein 17555331
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Camptothecin results in increased stability of and results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein increases activity
/ increases expression
/ increases phosphorylation
/ increases stability
protein 11741290
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 S-ethyl glutathione inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] decreases reaction
/ increases expression
protein 17555331
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 TP53 protein mutant form results in decreased susceptibility to Camptothecin decreases response to substance
protein 10692111
D002166 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 TP53 protein results in increased susceptibility to Camptothecin increases response to substance
protein 9673414
23285096
D002166 9540 TP53I3
PIG3
tumor protein p53 inducible protein 3 Camptothecin results in increased expression of TP53I3 mRNA increases expression
mRNA 17374387
D002166 11257 TP53TG1
LINC00096
NCRNA00096
P53TG1
P53TG1-D
TP53AP1
TP53 target 1 (non-protein coding) Camptothecin results in increased expression of TP53TG1 mRNA increases expression
mRNA 17374387
D002166 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) Camptothecin results in increased expression of TYMS mRNA increases expression
mRNA 16568373
D002166 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Camptothecin results in decreased expression of VEGFA protein decreases expression
protein 20116850
D002166 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A VEGFA protein results in decreased susceptibility to Camptothecin decreases response to substance
protein 16356833
D002166 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis [Butyrates co-treated with Camptothecin] results in decreased expression of XIAP protein affects cotreatment
/ decreases expression
protein 16061681
D002166 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis [Camptothecin co-treated with FAS protein] results in decreased expression of XIAP protein affects cotreatment
/ decreases expression
protein 19633536
D002166 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis XIAP protein results in decreased susceptibility to Camptothecin decreases response to substance
protein 16211302
D002166 7518 XRCC4
X-ray repair complementing defective repair in Chinese hamster cells 4 XRCC4 results in decreased susceptibility to Camptothecin decreases response to substance
21785230

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (99)

OMIM preferred title UniProt
#300438 17-beta-hydroxysteroid dehydrogenase x deficiency Q99714
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#609135 Aplastic anemia O14746
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#613985 Beta-thalassemia P68871
#603902 Beta-thalassemia, dominant inclusion body type P68871
#210900 Bloom syndrome; blm P54132
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
#300615 Brunner syndrome P21397
#115200 Cardiomyopathy, dilated, 1a; cmd1a P02545
#212112 Cardiomyopathy, dilated, with hypergonadotropic hypogonadism P02545
#118300 Charcot-marie-tooth disease and deafness Q01453
#605588 Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 P02545
#118220 Charcot-marie-tooth disease, demyelinating, type 1a; cmt1a Q01453
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#119900 Digital clubbing, isolated congenital P15428
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#613989 Dyskeratosis congenita, autosomal dominant, 2; dkca2 O14746
#181350 Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 P02545
#226980 Epiphyseal dysplasia, multiple, with early-onset diabetes mellitus Q9NZJ5
#133239 Esophageal cancer P04637
#615363 Estrogen resistance; estrr P03372
#301500 Fabry disease P06280
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#608013 Gaucher disease, perinatal lethal P04062
#230800 Gaucher disease, type i P04062
#230900 Gaucher disease, type ii P04062
#231000 Gaucher disease, type iii P04062
#231005 Gaucher disease, type iiic P04062
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#137800 Glioma susceptibility 1; glm1 P04626
#232300 Glycogen storage disease ii P10253
#139393 Guillain-barre syndrome, familial; gbs Q01453
#605130 Hairy elbows, short stature, facial dysmorphism, and developmental delay Q03164
#610140 Heart-hand syndrome, slovenian type P02545
#140700 Heinz body anemias P68871
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#143100 Huntington disease; hd P42858
#176670 Hutchinson-gilford progeria syndrome; hgps P02545
#145000 Hyperparathyroidism 1; hrpt1 O00255
#603373 Hyperthyroidism, familial gestational P16473
#609152 Hyperthyroidism, nonautoimmune P16473
#145900 Hypertrophic neuropathy of dejerine-sottas Q01453
#259100 Hypertrophic osteoarthropathy, primary, autosomal recessive, 1; phoar1 P15428
#275200 Hypothyroidism, congenital, nongoitrous, 1; chng1 P16473
#612244 Inflammatory bowel disease 13; ibd13 P08183
#603932 Intervertebral disc disease; idd P14780
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#151660 Lipodystrophy, familial partial, type 2; fpld2 P02545
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
P04637
#608516 Major depressive disorder; mdd P08172
#248370 Mandibuloacral dysplasia with type a lipodystrophy; mada P02545
#615134 Melanoma, cutaneous malignant, susceptibility to, 9; cmm9 O14746
#300705 Mental retardation, x-linked 17; mrx17 Q99714
%300852 Mental retardation, x-linked 88; mrx88 P50052
#300220 Mental retardation, x-linked, syndromic 10; mrxs10 Q99714
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#131100 Multiple endocrine neoplasia, type i; men1 O00255
#126200 Multiple sclerosis, susceptibility to; ms P08575
#613205 Muscular dystrophy, congenital, lmna-related P02545
#159001 Muscular dystrophy, limb-girdle, type 1b; lgmd1b P02545
#159900 Myoclonic dystonia P14416
#160900 Myotonic dystrophy 1; dm1 Q9NR56
#162500 Neuropathy, hereditary, with liability to pressure palsies; hnpp Q01453
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#260500 Papilloma of choroid plexus; cpp P04637
#168600 Parkinson disease, late-onset; pd P04062
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#614742 Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1; pfbmft1 O14746
#178500 Pulmonary fibrosis, idiopathic; ipf O14746
#607276 Resting heart rate, variation in P08588
#275210 Restrictive dermopathy, lethal P02545
#604906 Schizophrenia 9; sczd9 P49798
#181500 Schizophrenia; sczd P49798
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#603903 Sickle cell anemia P68871
#253300 Spinal muscular atrophy, type i; sma1 Q16637
#253550 Spinal muscular atrophy, type ii; sma2 Q16637
#253400 Spinal muscular atrophy, type iii; sma3 Q16637
#271150 Spinal muscular atrophy, type iv; sma4 Q16637
#183090 Spinocerebellar ataxia 2; sca2 Q99700
#275355 Squamous cell carcinoma, head and neck; hnscc P04637
#187950 Thrombocythemia 1; thcyt1 P40225
#190300 Tremor, hereditary essential, 1; etm1 P35462
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (97)

KEGG disease name UniProt
H00033 Adrenal carcinoma O00255 (related)
P04637 (related)
H00034 Carcinoid O00255 (related)
H00045 Malignant islet cell carcinoma O00255 (related)
H00246 Primary hyperparathyroidism O00255 (related)
H01102 Pituitary adenomas O00255 (related)
H00764 Cri du chat syndrome O14746 (related)
H01132 Aplastic anemia (AA) O14746 (related)
H01299 Idiopathic pulmonary fibrosis O14746 (related)
H00022 Bladder cancer O14746 (marker)
P00533 (related)
P04626 (related)
P04637 (related)
P68871 (marker)
H00024 Prostate cancer O14746 (marker)
H00016 Oral cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P00533 (related)
P04637 (related)
P04637 (marker)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
P04637 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
P04637 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00264 Charcot-Marie-Tooth disease (CMT) P02545 (related)
Q01453 (related)
H00294 Dilated cardiomyopathy (DCM) P02545 (related)
H00420 Familial partial lipodystrophy (FPL) P02545 (related)
H00563 Emery-Dreifuss muscular dystrophy P02545 (related)
H00590 Congenital muscular dystrophies (CMD/MDC) P02545 (related)
H00593 Limb-girdle muscular dystrophy (LGMD) P02545 (related)
H00601 Hutchinson-Gilford progeria syndrome P02545 (related)
H00663 Restrictive dermopathy P02545 (related)
H00665 Mandibuloacral dysplasia P02545 (related)
H01216 Left ventricular noncompaction (LVNC) P02545 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
P04637 (related)
Q92731 (marker)
H00066 Lewy body dementia (LBD) P04062 (related)
H00126 Gaucher disease P04062 (related)
H00426 Defects in the degradation of ganglioside P04062 (related)
H00810 Progressive myoclonic epilepsy (PME) P04062 (related)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
P04637 (related)
P04637 (marker)
H00027 Ovarian cancer P04626 (related)
P04637 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
P04637 (related)
H00046 Cholangiocarcinoma P04626 (related)
P04637 (related)
P35354 (related)
H00004 Chronic myeloid leukemia (CML) P04637 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
P68871 (marker)
H00025 Penile cancer P04637 (related)
P04637 (marker)
P14780 (related)
P35354 (related)
H00029 Vulvar cancer P04637 (related)
H00032 Thyroid cancer P04637 (related)
H00036 Osteosarcoma P04637 (related)
P08684 (marker)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
H00044 Cancer of the anal canal P04637 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00125 Fabry disease P06280 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00069 Glycogen storage diseases (GSD) P10253 (related)
H01205 Coumarin resistance P11712 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00457 Primary hypertrophic osteoarthropathy (PHO) P15428 (related)
H01246 Isolated congenital nail clubbing (ICNC) P15428 (related)
H00250 Congenital nongoitrous hypothyroidism (CHNG) P16473 (related)
H01269 Congenital hyperthyroidism P16473 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00227 Congenital amegakaryocytic thrombocytopenia (CAMT) P40225 (marker)
H00059 Huntington's disease (HD) P42858 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
Q99714 (related)
H00094 DNA repair defects P54132 (related)
H00296 Defects in RecQ helicases P54132 (related)
H00228 Thalassemia P68871 (related)
H00229 Sickle cell anemia (SCA) P68871 (related)
H01296 Hereditary neuropathy with liability to pressure palsies (HNPP) Q01453 (related)
H00001 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Q03164 (related)
Q03164 (marker)
H00002 Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) Q03164 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00455 Spinal muscular atrophy (SMA) Q16637 (related)
Q16637 (related)
H00063 Spinocerebellar ataxia (SCA) Q99700 (related)
H00658 Syndromic X-linked mental retardation Q99714 (related)
H00925 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency Q99714 (related)
H00512 Permanent neonatal diabetes mellitus (PNDM) Q9NZJ5 (related)
H00766 Wolcott-Rallison syndrome Q9NZJ5 (related)

Diseases related to CTD interactions

11 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D003967 D002166 Diarrhea marker/mechanism
9149702
D005621 D002166 Friedreich Ataxia therapeutic
23418481
D005910 D002166 Glioma therapeutic
12650430
D018316 D002166 Gliosarcoma therapeutic
15197484
D006816 D002166 Huntington Disease therapeutic
21909362
D007945 D002166 Leukemia, Lymphoid therapeutic
9921918
D007968 D002166 Leukoencephalopathy, Progressive Multifocal therapeutic
9149702
D009369 D002166 Neoplasms therapeutic
18492797
D009374 D002166 Neoplasms, Experimental therapeutic
7707314
D009503 D002166 Neutropenia marker/mechanism
9149702
D024801 D002166 Tauopathies therapeutic
16930453